Dermapharm Forecast, price target & analysts
Dermapharm Target price 2026 - Analyst rating & recommendation
Dermapharm Classifications & Recommendation
Dermapharm Price Target
| Target Price | €51.00 |
| Price | €39.05 |
| Potential |
30.60%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Dermapharm 2027 .
The average Dermapharm target price is €51.00.
This is
30.60%
register free of charge
€63.00
61.33%
register free of charge
€44.44
13.80%
register free of charge
|
|
| A rating was issued by 9 analysts: 7 Analysts recommend Dermapharm to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Dermapharm stock has an average upside potential 2027 of
30.60%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion € | 1.16 | 1.22 |
| 1.34% | 4.29% | |
| EBITDA Margin | 27.28% | 28.35% |
| 5.26% | 3.93% | |
| Net Margin | 11.37% | 10.96% |
| 17.94% | 3.57% |
6 Analysts have issued a sales forecast Dermapharm 2026 . The average Dermapharm sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Dermapharm EBITDA forecast 2026. The average Dermapharm EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Dermapharm Analysts have issued a net profit forecast 2026. The average Dermapharm net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share € | 2.46 | 2.69 |
| 16.59% | 9.35% | |
| P/E | 14.52 | |
| EV/Sales | 2.38 |
6 Analysts have issued a Dermapharm forecast for earnings per share. The average Dermapharm EPS is
This results in the following potential growth metrics and future valuations:
Current Dermapharm Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Locked
➜
Locked
|
Locked | Sep 21 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Sep 03 2026 |
| MWB RESEARCH AG |
Locked
➜
Locked
|
Locked | Aug 25 2026 |
| ODDO BHF |
Locked
➜
Locked
|
Locked | Aug 25 2026 |
| ODDO BHF |
Locked
➜
Locked
|
Locked | Jun 23 2026 |
| ODDO BHF |
Locked
➜
Locked
|
Locked | Jun 22 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | May 27 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BERENBERG:
Locked
➜
Locked
|
Sep 21 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Sep 03 2026 |
|
Locked
MWB RESEARCH AG:
Locked
➜
Locked
|
Aug 25 2026 |
|
Locked
ODDO BHF:
Locked
➜
Locked
|
Aug 25 2026 |
|
Locked
ODDO BHF:
Locked
➜
Locked
|
Jun 23 2026 |
|
Locked
ODDO BHF:
Locked
➜
Locked
|
Jun 22 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
May 27 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
